Abstract:Abstract Introduction Parkinson’s disease (PD) is a progressive neurodegenerative disorder characterized by pathognomonic motor abnormalities that lead to significant disability and morbidity in advanced stages. PD is also associated with sleep abnormalities such as increased fragmentation, insomnia, and excessive daytime sleepiness. Little is known of the underlying mechanisms, in part due to the limited ability of existing mouse models to adequately replicate human PD patient sleep phenotypes. Here we characterize sleep-wake behavior in an innovative genetic mouse model of PD (MCI-Park) targeting a mitochondrial complex I gene (Ndufs2), which experiences progressive dopaminergic neuron loss and displays motor phenotypes resembling those seen in human PD. Methods Undisturbed sleep-wake behavior during 12 hr light: 12 hr dark cycles was evaluated in MCI-Park mice during prodromal stages (6-8 weeks of age) and later parkinsonian stages (14-18 weeks of age) as well as in age-matched wildtype littermate controls. Electroencephalographic (EEG) and electromyographic (EMG) recording electrodes were surgically implanted using sterile technique in male and female MCI-Park and wildtype mice. After one week of recovery and acclimation to recording chambers, EEG and EMG were recorded continuously and sleep phenotypes were analyzed. Results In prodromal stages, MCI-Park mice exhibited similar overall sleep state amounts compared to wildtype mice, however there were significantly more state shifts as well as longer bouts of wakefulness and shorter bouts of non-REM (NREM) sleep. As mice progressed to parkinsonian stages, these fragmentation measures worsened. In addition, parkinsonian MCI-Park mice experienced a significant increase in wakefulness, a significant reduction in NREM sleep amount, and alterations in REM sleep, with pronounced reductions in REM sleep amount and number of REM bouts. Power spectral analysis revealed consistent decreases in theta2 (also known as alpha) power across all sleep-wake states in MCI-Park mice. Conclusion These results indicate that mice harboring a genetic defect causing selective disruption of dopaminergic neurons exhibit progressive sleep abnormalities that resemble sleep disturbances in PD patients. This model thus offers an opportunity to evaluate mechanisms underlying and therapeutic strategies targeting altered sleep in PD patients. Support (if any) This work was supported by the Department of Defense award number W81XWH-21-0582 (F.W.T. and D.J.S.).

Propagated α-synucleinopathy recapitulates REM sleep behaviour disorder followed by parkinsonian phenotypes in mice

An Accelerated Parkinson’s Disease Monkey Model Using AAV-α-synuclein Plus Poly(adp-Ribose)

GBA-AAV mitigates sleep disruptions and motor deficits in mice with REM sleep behavior disorder

Cell-to-cell transmitted alpha-synuclein recapitulates experimental Parkinson’s disease

Different Patterns of Exosomal Α‐synuclein Between Parkinson's Disease and Probable Rapid Eye Movement Sleep Behavior Disorder

Wider and Faster Degeneration of White Matter in Parkinson’s Disease with Possible REM Sleep Behaviour Disorder

Pharmacological interventions targeting α-synuclein aggregation triggered REM sleep behavior disorder and early development of Parkinson's disease

Gut-Initiated Alpha Synuclein Fibrils Drive Parkinson’s Disease Phenotypes: Temporal Mapping of non-Motor Symptoms and REM Sleep Behavior Disorder

0258 Altered sleep regulation in a mouse model of Parkinson’s disease

Olfactory deficit and gastrointestinal dysfunction precede motor abnormalities in alpha-Synuclein G51D knock-in mice

Rapid Eye Movement Sleep Behavior Disorder As a Predicting Phenomenon of Α-Synucleinopathies( Report of 1 Case)

Symmetric and Profound Monoaminergic Degeneration in Parkinson's Disease with Premotor REM Sleep Behavior Disorder

Biomarkers of conversion to α-synucleinopathy in isolated rapid-eye-movement sleep behaviour disorder

Presynaptic Dopaminergic Imaging Characterizes Patients with REM Sleep Behavior Disorder Due to Synucleinopathy

Biomarkers of conversion to -synucleinopathy in isolated rapid-eye-movement sleep behaviour disorder

α-Synuclein reduces acetylserotonin O-methyltransferase mediated melatonin biosynthesis by microtubule-associated protein 1 light chain 3 beta-related degradation pathway

Impaired Ocular Tracking and Cortical Atrophy in Idiopathic Rapid Eye Movement Sleep Behavior Disorder

Rapid Eye Movement Sleep Behavior Disorder and Neurodegenerative Diseases: An Update

Possible predictors of phenoconversion in isolated REM sleep behaviour disorder: a systematic review and meta-analysis

Altered Motor Performance, Sleep EEG, and Parkinson's Disease Pathology Induced by Chronic Sleep Deprivation in Lrrk2G2019S Mice

Predictors of Conversion to -Synucleinopathy Diseases in Idiopathic Rapid Eye Movement Sleep Behavior Disorder